| Washington University in St. Louis | |
|---|---|
| Logo placeholder | |
| Location | St. Louis, MO, USA |
| Type | Research University |
| Website | https://wustl.edu/ |
| Focus Areas | Alzheimer's Disease, Amyloid Biology, Biomarkers, Neuroimaging |
| Departments | Knight Alzheimer's Disease Research Center Department of Neurology Hope Center for Neurological Disorders |
Washington University In St. Louis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Washington University in St. Louis (WashU) is a private research university renowned for its excellence in biomedical research, particularly in the field of neurodegenerative diseases.[1] The university's Knight Alzheimer's Disease Research Center (ADRC) is one of the original NIH-funded Alzheimer's Disease Research Centers and has been at the forefront of Alzheimer's disease research for over four decades.[2]
WashU's neuroscience research enterprise spans multiple schools and departments, creating a highly collaborative environment for investigating the mechanisms, diagnosis, and treatment of Alzheimer's disease and related disorders.[3]
The Knight Alzheimer's Disease Research Center at Washington University is a premier research facility dedicated to understanding Alzheimer's disease from its earliest preclinical stages through advanced dementia.[4] The center operates several major research programs:
WashU pioneered the characterization of preclinical Alzheimer's disease, identifying biomarker changes that occur years before clinical symptoms appear.[5] This work has been instrumental in developing prevention trials targeting individuals in the preclinical stage.
The Knight ADRC maintains one of the world's largest collections of cerebrospinal fluid and plasma samples from well-characterized research participants, enabling longitudinal studies of biomarker changes throughout disease progression.[6]
WashU researchers have developed advanced neuroimaging techniques for visualizing amyloid plaques, tau tangles, and neurodegeneration in living individuals, contributing to the National Institute on Aging's amyloid/tau/neurodegeneration (ATN) research framework.[7]
Washington University researchers have made numerous seminal contributions to Alzheimer's disease research:
| Researcher | H-index | Focus Areas |
|---|---|---|
| [David M. Holtzman[/researchers/[david-holtzman[/researchers/[david-holtzman[/researchers/[david-holtzman--TEMP--/researchers)--FIX-- | 200 | Alzheimer's Disease, Biomarkers, Sleep |
| [John C. Morris[/researchers/[john-morris[/researchers/[john-morris[/researchers/[john-morris--TEMP--/researchers)--FIX-- | 150 | Alzheimer's Disease, Clinical Trials, Biomarkers |
| [Randall J. Bateman[/researchers/[randall-bateman[/researchers/[randall-bateman[/researchers/[randall-bateman--TEMP--/researchers)--FIX-- | 100 | Alzheimer's Disease, Biomarkers, Clinical Trials |
The Hope Center for Neurological Disorders brings together researchers studying a broad range of neurological conditions, including Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis.[13] The center supports collaborative research projects, pilot grants, and training programs.
The study of Washington University In St. Louis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page auto-generated from NeuroWiki institution database. Last updated: 2026-03-03.